2026-01-04 - Analysis Report
Okay, here's a breakdown and analysis of TMDX, based on the provided data.

**1) Performance vs. S&P 500 (VOO)**

*   **Company Overview:** Transmedics Group Inc is a medical technology company focused on developing and delivering technologies for improved organ preservation for transplantation.
*   **TMDX Cumulative Return:** 199.45%
*   **VOO Cumulative Return:** 70.76%
*   **Divergence:** 128.7
*   **Relative Divergence:** 62.2

**Analysis:** TMDX has significantly outperformed the S&P 500. A divergence of 128.7 indicates a substantial absolute difference in cumulative returns. The relative divergence of 62.2 suggests the current divergence is in the middle of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha | Beta | Cap(B) |
|------------|--------|-------|-------|------|--------|
| 2020-2022  | 94.0%  | 60.2% | 96.0% | 1.3  | 2.1    |
| 2021-2023  | 65.0%  | 60.2% | 64.0% | 1.7  | 2.7    |
| 2022-2024  | 130.0% | 51.7% | 111.0% | 1.8  | 2.1    |
| 2023-2025  | 120.0% | 53.4% | 58.0% | 1.4  | 4.2    |

**Analysis:**

*   **CAGR:** TMDX shows very strong Compound Annual Growth Rates across all periods.
*   **MDD:** Maximum Drawdown figures are relatively high, indicating significant volatility and potential risk of losses.
*   **Alpha:** Consistently high Alpha values indicate the stock has outperformed its benchmark even when accounting for market risk.  This is a strong positive.
*   **Beta:** Beta values are generally above 1, meaning the stock is more volatile than the S&P 500. The Beta seems to be trending downwards in recent period.
*   **Cap(B):** Market Cap in Billions (B), demonstrating the company's size and market influence.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 122.69
*   **Previous Close:** 121.65
*   **Change:** 0.85
*   **5-day SMA:** 122.704
*   **20-day SMA:** 127.454
*   **60-day SMA:** 126.3023

**Analysis:**

*   The recent close is slightly higher than the previous close, indicating a small upward movement.
*   The 5-day SMA is roughly equal to the current price, suggesting recent price stability.
*   The 20-day SMA is higher than the 60-day SMA, and both are above the current price. This suggests a short-term downward trend as the price is below its recent averages.

**3) Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 40.99
*   **PPO:** -0.64
*   **Hybrid Signal:** Buy 100% (7 shares, Very Safe, MRI: 0.90, Monthly Invest 1.2%)
*   **Recent Relative Divergence Change:** -3.1 (short-term decline)
*   **Expected Return (%):** 56.4%

**Analysis:**

*   **MRI:** A MRI of 0.8 suggests a medium level of investment risk, indicating a reasonable balance between risk and potential return.
*   **RSI:** An RSI of 40.99 is below 50, indicating the stock isn't overbought and might have room to move upwards. However, it's not oversold either.
*   **PPO:** A negative PPO (-0.64) suggests the stock is in a downtrend, but the value is fairly small.
*   **Hybrid Signal:** The "Buy 100%" signal, combined with "Very Safe," suggests a strong positive outlook based on the indicator's specific calculations.
*   **Recent Relative Divergence Change:** The recent relative divergence decrease indicates a short-term negative trend.
*   **Expected Return:** A 56.4% expected return is extremely high and bullish, suggesting the model believes the stock is significantly undervalued.

**4) Recent News & Significant Events**

*   **Positive Q3 Earnings Beat (Oct 2025):** Despite the "falls" headline, the article highlights that the company *beat* earnings estimates, and revenues were up year-over-year. This is a positive fundamental signal.
*   **Reasons to Retain TransMedics Stock (Dec 2025):**  This explicitly suggests a hold/buy recommendation.
*   **Under-the-Radar Stock Soaring (Dec 2025):** Highlights strong performance and potential undervaluation.
*   **Insider Sales & Eventide Sells Shares (Dec 2025):** Insider sales and large institutional sales can be perceived as negative signals. However, they could be for various reasons (profit taking, portfolio rebalancing).
*   **Trading the Move (Jan 2026):** Suggests focus on short term trading opportunities.

**Analysis:** The news is mixed.  Positive earnings, retain recommendations, and "soaring" stories are bullish. Insider sales and Eventide selling shares are bearish.

**4-2) Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.67 (Buy)
*   **Target Price:** Average: 144.73 / High: 170.00 / Low: 114.00

**Analysis:** Analysts are generally positive on TMDX, with a consensus "Buy" rating. The average target price of $144.73 indicates a potential upside of approximately 18% from the current price of $122.69.

**5) Comprehensive Analysis & Summary**

TMDX presents a complex picture.

**Positives:**

*   **Strong Historical Performance:**  Significant outperformance vs. S&P 500 and high CAGR.
*   **High Alpha:** The stock is generating returns independent of market movements.
*   **Positive Analyst Ratings:**  Consensus "Buy" with significant upside potential in target price.
*   **Positive News:** Recent earnings beat and recommendations to retain the stock.
*   **High Expected Return:** Indicator predicts a high expected return.

**Negatives/Risks:**

*   **High Volatility:** High MDD and Beta indicate significant price swings.
*   **Recent Downward Trend:** Price below moving averages and recent negative relative divergence change.
*   **Insider Sales/Institutional Selling:** Potentially concerning, but could be due to various reasons.
*   **Small Negative PPO:** Indicator shows a slight down trend.

**Conclusion:**

TMDX appears to be a growth stock with strong potential, but also significant risk.  The high Alpha, CAGR, and positive analyst sentiment are compelling. However, the high volatility, recent price weakness, and insider sales are warning signs. The high expected return and "Very Safe" buy signal from the hybrid indicator should be interpreted with caution, given the contrasting short term trend.

**Recommendation:**

Given the mixed signals, a cautious approach is warranted.
*   **Aggressive Investors:**  Might consider a position in TMDX, acknowledging the volatility and potential for short-term losses, but expecting long-term gains.
*   **Conservative Investors:** Should be wary of the stock's volatility and may want to wait for a clearer uptrend or consider a smaller position.

**Disclaimer:** This is an AI-generated analysis and should not be taken as financial advice. Always conduct thorough research and consult with a qualified financial advisor before making investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.